Amgen Moves Closer to Selling Competitor for AbbVie’s Humira

  • FDA advisers vote 26-0 for Amgen’s biosimilar to be approved
  • Humira is AbbVie’s top-selling drug at $14 billion last year

Amgen Inc.’s biosimilar version of the arthritis drug Humira cleared a regulatory hurdle, bringing it closer to entering the U.S. market and providing competition that could lower prices for AbbVie Inc.’s best-selling treatment.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.